BIOMAT Database Logo BIOMAT Database Logo

Accumulation of 2-amino-6-methyldipyrido[1,2-a:3',2'-d]imidazole and 2-aminodipyrido[1,2-a:3',2'-d]imidazole, carcinogenic glutamic acid pyrolysis products, in plasma of patients with uremia. 1987

S Manabe, and H Yanagisawa, and S Ishikawa, and Y Kitagawa, and Y Kanai, and O Wada
Department of Hygiene and Preventive Medicine, Faculty of Medicine, University of Tokyo, Japan.

In order to investigate the exposure of humans to 2-amino-6-methyldipyrido[1,2-a:3',2'-d]imidazole [(Glu-P-1) Chemical Abstracts Service:67730-11-4] and 2-aminodipyrido[1,2-a:3',2'-d]imidazole [(Glu-P-2) Chemical Abstracts Service:67730-10-3], carcinogenic heterocyclic amines, we developed a high-performance liquid chromatography method to detect Glu-P-1 and Glu-P-2 in biological samples, and compared the plasma levels of the carcinogens in normal subjects with those in uremic patients in which higher incidence of malignancy has been reported. Glu-P-1 and Glu-P-2 levels in plasma of uremic patients before induction of hemodialysis treatment were 12.62 +/- 3.65 (SD) pmol/ml (n = 5) and 14.81 +/- 5.17 pmol/ml (n = 5), respectively, whereas Glu-P-1 and/or Glu-P-2 could be detected in only two of seven normal subjects and the levels were lower than 3.1 pmol/ml. Approximately 10% of these carcinogens in plasma of uremic patients could be removed by the first hemodialysis treatment, and reasonable amounts of these carcinogens could be detected in the dialysate of uremic patients. However, significant amounts of Glu-P-1 and Glu-P-2 were still detected in plasma of all uremic patients even after 1 month-hemodialysis treatments. These results suggest that one of the excretory pathways of these carcinogens is via kidney.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D002273 Carcinogens Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. Carcinogen,Oncogen,Oncogens,Tumor Initiator,Tumor Initiators,Tumor Promoter,Tumor Promoters,Initiator, Tumor,Initiators, Tumor,Promoter, Tumor,Promoters, Tumor
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D014511 Uremia A clinical syndrome associated with the retention of renal waste products or uremic toxins in the blood. It is usually the result of RENAL INSUFFICIENCY. Most uremic toxins are end products of protein or nitrogen CATABOLISM, such as UREA or CREATININE. Severe uremia can lead to multiple organ dysfunctions with a constellation of symptoms. Uremias

Related Publications

S Manabe, and H Yanagisawa, and S Ishikawa, and Y Kitagawa, and Y Kanai, and O Wada
Metabolic activation of glutamic acid pyrolysis products, 2-amino-6-methyldipyrido[1,2-a:3',2'-d]imidazole and 2-amino-dipyrido[1,2-a:3',2'-d]imidazole, by purified cytochrome P-450.
December 1981, Chemico-biological interactions,
S Manabe, and H Yanagisawa, and S Ishikawa, and Y Kitagawa, and Y Kanai, and O Wada
Sequence selective modification of DNA with muta-carcinogenic 2-amino-6-methyldipyrido[1,2-a:3',2'-d]imidazole.
November 1983, Biochemical and biophysical research communications,
S Manabe, and H Yanagisawa, and S Ishikawa, and Y Kitagawa, and Y Kanai, and O Wada
Glu-P-1 (2-amino-6-methyldipyrido[1,2-a:3',2'-d]imidazole).
January 1986, IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans,
S Manabe, and H Yanagisawa, and S Ishikawa, and Y Kitagawa, and Y Kanai, and O Wada
Metabolic activation of a mutagen, 2-amino-6-methyldipyrido-[1,2-a:3',2'-d]imidazole. Identification of 2-hydroxyamino-6-methyldipyrido [1,2-a:3',2'-d]imidazole and its reaction with DNA.
February 1980, Biochemical and biophysical research communications,
S Manabe, and H Yanagisawa, and S Ishikawa, and Y Kitagawa, and Y Kanai, and O Wada
Tumor induction in mice administered neonatally with 2-amino-6-methyldipyrido[1,2-a:3',2'-d]imidazole or 2-amino-dipyrido[1,2-a:3',2'-d]imidazole.
July 1988, Cancer letters,
S Manabe, and H Yanagisawa, and S Ishikawa, and Y Kitagawa, and Y Kanai, and O Wada
Activation of 2-amino-6-methyldipyrido[1,2-a:3' ,2' -d]imidazole, a mutagenic pyrolysis product of glutamic acid, to bind to microsomal protein by NADPH-dependent and -independent enzyme systems.
May 1984, Carcinogenesis,
S Manabe, and H Yanagisawa, and S Ishikawa, and Y Kitagawa, and Y Kanai, and O Wada
Glu-P-2 (2-aminodipyrido[1,2-a:3',2'-d]imidazole).
January 1986, IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans,
S Manabe, and H Yanagisawa, and S Ishikawa, and Y Kitagawa, and Y Kanai, and O Wada
Presence of 2-aminodipyrido[1,2-a:3',2'-d]imidazole in casein pyrolysate.
December 1979, Gan,
S Manabe, and H Yanagisawa, and S Ishikawa, and Y Kitagawa, and Y Kanai, and O Wada
Presence of 2-aminodipyrido[1,2-a: 3',2'-d]imidazole in broiled cuttlefish.
October 1980, Gan,
S Manabe, and H Yanagisawa, and S Ishikawa, and Y Kitagawa, and Y Kanai, and O Wada
N-acetyl derivative as the major active metabolite of 2-amino-6-methyldipyrido[1,2-a:3',2'-d]imidazole in rat bile.
September 1986, Mutation research,
Copied contents to your clipboard!